Cerenion receives funding from the EU for a 222,000€ project
The grant for a project of approximately 222,000€ has been given to Cerenion for the development of an ISO13485 -certified Quality Management System and the related work in seeking the appropriate regulatory approvals.The non-dilutive funding will assist the company in bringing its innovative brain monitoring technology to the European Union market.
”We are grateful to the European Regional Development Fund, the European Union and the Centre for Economic Development, Transport and the Environment in North Ostrobothnia for this grant. Aided by the grant we feel confident that we can bring our novel solution to the healthcare market in due time and really make a difference in the care of ICU patients,” said Dr. Timo Koskela, CEO of Cerenion.
Cerenion develops the world’s first practical method for measuring the brain function of intensive care patients. The Cerenion C-Trend™ technology (pat. pend.) aims to reveal the status of the brain as one simple score – at the bed-side and without requiring any changes to the care of the patient.